According to the quarterly report released by Tianjin Ringpu Bio-Technology Co., Ltd. (300119.SZ), the company achieved a revenue of 2.544 billion Yuan for the first three quarters of 2025, reflecting a year-on-year increase of 13.50%. The net profit attributable to shareholders reached 362 million Yuan, a substantial increase of 45.64% compared to the previous year. The net profit attributable to shareholders, excluding non-recurring gains and losses, was 269 million Yuan, an increase of 24.92% year-on-year. The basic earnings per share stood at 0.7972 Yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments